Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.

[1]  L. Lund,et al.  Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. , 2015, European heart journal.

[2]  C. Morgan,et al.  Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. , 2015, The American journal of medicine.

[3]  K. Lohr,et al.  Transitional Care Interventions to Prevent Readmissions for Persons With Heart Failure , 2014, Annals of Internal Medicine.

[4]  J. Fleg,et al.  Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. , 2014, The American journal of medicine.

[5]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[6]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[7]  J. Fleg,et al.  Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. , 2013, The American journal of medicine.

[8]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[9]  R. Allman,et al.  Baseline characteristics, quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart failure: findings from the Alabama Heart Failure Project. , 2012, International journal of cardiology.

[10]  M. Rich,et al.  Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. , 2012, The American journal of medicine.

[11]  M. Hernán,et al.  Systematic Reviews and Meta-and Pooled Analyses Bias in Observational Studies of Prevalent Users : Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins , 2012 .

[12]  Mark V. Williams,et al.  Rehospitalizations among patients in the Medicare fee-for-service program. , 2009, The New England journal of medicine.

[13]  W. Aronow,et al.  A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. , 2009, European heart journal.

[14]  Straube Bm,et al.  Rehospitalizations among patients in the Medicare fee-for-service program. , 2009 .

[15]  W. Aronow,et al.  A propensity-matched study of outcomes of chronic heart failure (HF) in younger and older adults. , 2009, Archives of gerontology and geriatrics.

[16]  G. Fonarow,et al.  Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. , 2009, Journal of the American College of Cardiology.

[17]  D. Rubin.  The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials , 2007, Statistics in medicine.

[18]  Nancy M Albert,et al.  Association between performance measures and clinical outcomes for patients hospitalized with heart failure. , 2007, JAMA.

[19]  M. Gheorghiade,et al.  Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. , 2006, European heart journal.

[20]  J. Butler,et al.  Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. , 2003, Journal of the American College of Cardiology.

[21]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[22]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[23]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[24]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[25]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .